OABI · OmniAb, Inc.
AI read · Neutral
The AI's read
OmniAb announced a global collaboration with Eli Lilly on an ion channel program and can earn up to $370 million plus tiered royalties. The company also raised 2026 cash guidance to $49–$53 million, extending runway. The market already reacted hard, with a double-digit premarket surge and RSI ~80 indicating the move is extended. Technical stretch increases the chance of sharp pullbacks after the pop. Our take is neutral. The headline deal is real but key terms like upfront size and the target are undisclosed, and much of the upside looks priced into the rally.